AstraZeneca has completed the resurrection of its anifrolumab drug for systemic lupus ... Benlysta has grown slowly towards its predicted blockbuster sales levels, just about breaching the $1 ...
After being all-but written off a year ago, AstraZeneca’s anifrolumab has been reborn ... and since then sales have grown steadily to reach more than $600 million last year.
Patients on anifrolumab spent more time in remission and low disease activity, and reached those states more quickly, vs. placebo. Achieving these states can stave off permanent organ damage.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback